Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

Cereno Scientific, Webcast, 2024

By Inderes9/30/2024, 12:00 PM
Cereno Scientific

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Sten Sörensen
00:00 - 20:23

Hello everyone. I'm Sten Sörensen and I'm the CEO of Cereno Scientific. Welcome to this webcast which highlights our top-line results of our lead drug in development, the HDAC inhibitor CS1 for the lethal disease, Pulmonary Arterial Hypertension. The focus of Cereno, we are passionate about developing new drugs that can improve quality of life and, if possible, extend life expectancy. So, those affected by cardiovascular disease will have the ability to play with their grandkids or live a fine life, despite having been diagnosed with the disease. Next, please. Today. On this webcast, I will be joined by Dr. Rahul Agrawal, who is Chief Medical Officer and Head of R&D. Our Chief Scientific Officer, Doctor Björn Dahlöf and our head of preclinical development, Nicholas Oakes. We will all share a few slides with you over approximately 1.5 hours, and at the end of that period, we'll have a few questions that we have received from the audience. And we expect the analysts, perhaps, to pose one or two questions that we do our best to answer for you next. So a few words about Suriano Scientific. The company was founded in 2012, and we believe we are pioneering epigenetic modulation through HDAC inhibition for cardiovascular diseases with disease-modifying potential. We have two programs with an HDAC inhibitor, of which we will focus on our lead program, CS1 today, where we have completed the Phase IIa trial in PAH, which has been conducted in the US at ten clinics. We will also refer to our second program, CS014, and some data that are very exciting for our programs as we move forward. And our pipeline is actually three programs. So the second program, CS014, is currently in a Phase I trial being run in Sweden, and we expect that trial to be completed by next summer. The third program we have is a novel pre-clinical process, a cyclin receptor agonist CS585, that we have licensed in from the University of Michigan, with whom we've had a collaboration effort going on for four years. We're listed on the Nasdaq First North Growth Market. Next please. So looking at our portfolio, of course, as a biotech, we'd like first and foremost that our ambitions and hard work will result in benefits for the patients. But the road to that benefit, both to the market and to the patients, sometimes involves collaborations, co-development, or even trade sales of our assets to partners in the industry. And so, we are developing our drugs, across three development programs, to be attractive not only to patients but also to collaborative partners. So if you look at our portfolio here to the right, we have a PAH program, which we will focus on today with our lead drug CS1. But we also then have a portfolio with our two programs CS014 and CS1. In addition, we have a thrombosis prevention portfolio where we have seen that we can prevent thrombosis without increasing bleeding risk. In our animal work, pursued at the University of Michigan, we explored both drugs; thrombosis is the number one killer in the world. Bleeding represents a significant unmet need in that market. Next, please. So, what are the latest news? You probably have seen the latest press releases if you're in this webcast and just want to reflect on those. So in our program in pH in phase two, we have actually applied for and received approval from the FDA for an extended access program. Of course, 1 in 5 patients who have completed the trial with CS1, which we have just concluded. So this provides the opportunity for patients to get access to the drug well before it is introduced to the market. And the judgment here by physicians in the trial and by patients willing to participate is that they have seen some benefits already in this trial and don't want to wait to get hold of the drug. We feel that there is a very strong signal that something positive is happening with the drug in these patients, experienced by both the physician and the patient. The program was approved on the 30th of January, and the first patient was just dosed. We recently communicated that. Another finding here that we have communicated from our HDAC inhibitor program is on our second development program, CS014. Last week, we released a communication confirming that this inhibitor has shown a dose-dependent impact on the severe changes in the pulmonary artery vessels. And we will hear more about that today by the head of those programs, Nicholas Oakes. That result, we feel, is underpinning our whole effort in this program towards the root cause in cardiovascular disease, not only but specifically in this case. In addition, of course, on Friday evening at 8:40 p.m., we released positive top-line results. Our lead program, CS1. And we will, of course, focus on that today. This morning, on the back of our findings or our scientific platform, I should say, which supports the entire ambition towards pH with HDAC inhibitors, and then the findings in the CS014 trial and, of course, the top line results. We communicated that we have established a partnership program with FLUIDDA, a cutting-edge and world-leading specialist, to visualize the reverse remodeling that could take place in arteries with our drug. And we are very much looking forward to seeing the impact in the clinical setting. From that microscopic perspective, so to speak. This morning we also communicated that we will hold the Capital Markets Day on October 17th. So a couple of weeks from now, it will be held in Stockholm and will also be webcast. And then there, we will spend three hours together, and there will be ample time to answer questions and elaborate on those. We will have guest speakers at that conference that you would be invited to hear more about our programs, what we've seen in the future. Next, please. So let's focus now on our FX program and the topline results. Next, please. So, this program is a Phase IIa trial. So the primary endpoint in such a program is safety and tolerability. So, the drug is safe and well-tolerated in a patient population. And that was met successfully in our trial. So, we met our primary endpoint. Another objective that we had with this trial was to harvest signals of efficacy. And we have seen very interesting, direct data. And we're excited about those. We have seen a 45% improvement in the REVEAL risk score, and 71% of the patients were both improved or stable. With regards to functional class, we observed that 33% of the patients improved and 86% of the patients were either improved or stable. With regards to a hemodynamic parameter, pulmonary arterial pressure in this case measured by CardioMEMS HF System. We saw that 67% of the patients had a sustained pressure reduction at the end of the period, which was 12 weeks. Now, see the study data here, along with the preclinical information we have on an HDAC inhibitor, specifically our active compound CS1. And then CS014 data are consistent with reversing pathological remodeling, which we aim to achieve with our drug. Based on these results, we believe we have a clear path forward. We will engage with regulatory authorities to pursue a pivotal trial, which will likely be a 2x3 trial. Next, please. So let's look at the agenda, and you can see we have a few points to cover. And this again will be quick, perhaps. But we would like to do this for you. So you get more information before the Capital Markets Day already. So let's move on. This Phase IIa trial aimed to enroll 30 patients and study them over a period of 12 weeks. On June 28th, we communicated that the decision had been made to close patient recruitment for this trial, which was completed on July 1st. The steering committee recommended Cereno Scientific to do so, as we believed we had gathered sufficient information from the trial to proceed with the next steps of our development program. This resulted in 25 patients being randomized and 21 patients analyzed for efficacy. We'll get to those numbers specifically later in the presentation. But this is the background. Next, please. So, let's return to the results of the trial. The primary endpoints of safety and tolerability were met successfully. What does that mean? Well, we had a good safety and tolerability profile. No CS1-related serious adverse events including hospitalization and mortality, no CS1-related changes in liver values, and no clinically significant CS1-related decreases in platelet count or bleeding. If we move on to tolerability. CS1 was well tolerated in the study. We'll get to more detail later on in the presentation next. With regards to the secondary ambition of this trial, let's look at the three main impacts that we've had in this trial as communicated thus far. So we will discuss the risk score. We have seen improvement in nine out of 21 patients. 71% or 15 out of 21 were improved or stable. And we will delve into what it means to improve the risk score. It has implications. If you're able to do that, you're doing something good for the patients, specifically when it comes to risk for the future. For functional class, seven out of 21 patients showed improvement. Improved functional class, and 18 out of 21 patients either maintained their class or improved. What does that mean? Well, functional class refers to the patient’s physical capacity to function in daily life. And we'll get into this. And I think Dr. Rahul Agrawal will, you know, explain more about what that means as we move on. And so those two important parameters, REVEAL risk score and functional class, showed quite some improvement or stability. If we move on to a specific parameter of hemodynamics, we saw that 14 out of 21, or 67% of the patients, had a sustained pressure reduction at the end or over the period of the trial, which was 12 weeks. And this was measured by the CardioMEMS technology, which we have implanted in these patients in a collaborative effort with Abbott, who owns the technology. So very good results for us, we believe. Let's move on. Now let's go into pulmonary hypertension. It's a progressive, debilitating, and fatal disease. There is no spontaneous improvement. That's important to note. It's a one-way road downhill until these patients, after a mean of seven and a half years, will not survive due to the disease. The disease. There is no cure except for lung transplantation today. Let's move on. Looking at this. In the animation to the right, you see a healthy lung. Then, this patient is experiencing pathological vascular remodeling. So the pulmonary arteries are becoming narrower. And then you create. That creates a higher pressure in these arteries, making it difficult for the heart to pump. So life expectancy before therapy, standard of care. Today, life expectancy before therapy, standard of care, was only two and a half years. Now with standard therapy or care, the life expectancy is seven and a half years. None of the current drugs are effectively addressing the root cause of the disease. And next, please. So what happens is that you have a healthy vessel. This is a pulmonary artery. And when you get to the early stage, it's narrower. As the disease progresses, the lumen becomes narrower, resulting in high pressure. And if you look to the right here, the pathophysiology involves endothelial dysfunction, inflammation, and fibrosis, which causes these vessels to become less compliant or flexible. And some plex-1 formulations appear. And then you have vasoconstriction, your vascular and right ventricular or right heart hypertrophy. And the clinical consequence of this is that the risk score and functional class in these patients deteriorate. Next, please. I should say that HDAC inhibition drives this development. Now, management goals, of course, include improving the REVEAL risk score and enhancing symptoms and physical capacity as measured by functional class. And it aims to improve hemodynamics as measured by pulmonary pressure and other metrics. So, CS1, the early drug, aims to achieve management goals by reversing pathological remodeling and achieving the goals mentioned above. Next. So more specifically, you'd like to improve the risk score status. You'd like to improve the functional class if possible, then of course hemodynamics. Often the key parameter here is pulmonary vascular resistance, which makes it difficult for blood to flow, for the right heart to pump, and for the mean pulmonary arterial pressure in those vessels to decrease. You'd like to improve right ventricular function. If you achieve this, you will extend survival in these patients. Next. So the key unmet need is that no drugs really address the root cause of the disease. You would like to introduce that to the patients. And you would like to do so with safer and more tolerable treatments than are currently on the market. CS1, our drug, aims to address these needs. So what's the scientific rationale for conducting a Phase IIa trial? Well, there is preclinical data that epigenetic modulation through HDAC inhibition provides an attractive proposition to address the root cause of PAH. Documentation of prevention and reversal of pathological remodeling and documentation of pulmonary arterial pressure reduction. All of these exist. So HDAC inhibition has the capacity and the characteristics to reverse pathological remodeling. It is an antifibrotic. It is anti-inflammatory and has been documented to reduce pulmonary pressure. It is an antithrombotic without an increased bleeding risk. Now, the majority of the data that has been published appeared in The Lancet Healthy Longevity, in a review article featuring the 100 most important articles related to this scientific platform. Next. So back here to what we would like to do and believe we are doing with our drug, the HDAC inhibitor CS1. You can see here the progression I showed before, and you see the blue line going back. So you'd like to prevent deterioration and then reverse this disease. So with the objective to improve the risk score and functional class. And this would be done by the parameters to the right, the characteristics of the drug that have already been published. Next. So looking at published data on our active ingredient VPA, you can see to the left here two graphs that have documented that you can both prevent and reverse the medial wall thickness in animals, particularly rats, in a pH model. And it's also measured here as vascular occlusive score. This was compared to a control group. And if you look to the right, the first graph shows that it's also been documented here that you can reduce the mean pulmonary arterial pressure in these models. Next. Now, what you'd like to do again, if you look to the right, is to achieve the clinical goal of therapies which is to improve the risk score and the functional class. So, if you could prevent progression, which is mentioned here in the middle, you would halt the deterioration of these patients. And that will make them have a better quality of life and live longer, if possible. You'd like to reverse the pathological remodeling, like what was seen in the animal work. So by that introduction, I'd like to introduce our head of R&D and Chief Medical Officer, Dr. Rahul Agrawal, please.

Dr. Rahul Agrawal
20:24 - 37:16

Thank you very much. Sten, allow me to go into a few details of the design and the goals of it to put things into perspective. I would like to go, of course, first into the primary endpoint of safety and tolerability. You've already heard about the very good results we have achieved and that we have met the primary endpoint. I'd like to briefly go also into exploring the efficacy parameters and the signals of reverse remodeling, why we undertook this approach, and why it is important. And of course, looking at these two, you have already heard about the good results we have; we are preparing to pursue a pivotal trial in collaboration with the regulatory authorities, the FDA and EMA. You're all aware of the Phase IIa trial design. The primary endpoint was safety and tolerability, which you have successfully met. We had also, of course, introduced exploratory endpoints like the validated risk score. I'll go into more detail regarding their functional class and hemodynamics. We used a very innovative method, CardioMEMS, which will allow a continuous measurement of hemodynamic parameters. I'll go into more detail there as well. Initially, we had planned for 30 patients, but as you heard from Stan at the evaluation of the clinical steering committee, we stopped the trial at 25 patients at ten US clinical sites. We had three dosages of 480, 960, and 1920 mg. But of course, due to the small size of the study, we pooled the data. Additionally, we pooled the data because our pharmacokinetic and pharmacodynamic (PK/PD) data indicated that we had already reached the maximum efficacious exposure at the lowest dosage. Our treatment period was 12 weeks. And please keep in mind that the treatment period was 12 weeks. Many of the studies in Phase III trials for pH later on were 24 weeks. So please look at it from that perspective. All in all, as we have stated, we have 25 randomized patients. That means 25 patients were used for the safety analysis. For the efficacy parameters, we have used 21 patients. It is called per protocol. That's a technical word. What does that mean? That means, all in all, we had 25 patients in the trial. However, four patients did not complete the trial. Three of them were already terminated and one had a protocol deviation. But none of it was study drug related. One patient withdrew consent. One patient had sepsis. That is practically inflammation of the body and blood. So that was unrelated to the drug. The third patient withdrew due to symptoms they experienced. As you know, these patients are multimorbid. They take many drugs. And it was for unspecific reasons. A fourth patient had to be excluded due to protocol deviation, as that patient was taking certain medications that were not allowed. So all in all, 25 patients were randomized. We used 25 patients for the safety analysis and 21 for the efficacy analyses. But the four that had to be excluded were not excluded for drug-related reasons. This is the baseline; if I may just briefly show, it is very representative of the population. Nearly 75% of the distribution were female. We had a good race distribution. Most of the patients were. And the inclusion criteria were a functional test at 40% and class III the rest. That is 60%. Allow me to briefly delve into the details and the importance of this. As you heard already from Sten. We are delighted to share that we have met the primary endpoint successfully, and we have a good safety and tolerability profile. If you look at the primary endpoint, we did not have a single drug-related serious adverse event, as you can see in the highlighted gray box, which is again very good news regarding the safety and tolerability profile. We did not see any CS1 related serious adverse events, including hospitalizations or mortality. We did not see any CS1 related changes in liver lab values, and we did not see any CS1 related clinically significant drug-related platelet decreases or bleeding. Something which, of course, everyone looks at. All in all, CS1 was well tolerated. So let us now turn our focus to the exploratory efficacy data. And I'd like to go into three areas which have already been mentioned. First of all, reduction in the REVEAL risk score, improvement in functional class, and reduction in a hemodynamic parameter. That is the mean pulmonary artery pressure measured with the CardioMEMS HF System from Abbott, with whom we have a close collaboration. And there we measured the area under the curve, which is AUC. So let us start with the REVEAL risk score. There are several risk scores, but the REVEAL risk score has shown to have the highest prognostic power. The author of this REVEAL risk score is also our principal investigator, Professor Doctor Benza. And here, these data have been published. One can see that, depending on which risk group one is in, the mortality and morbidity are already very high within 12 months. I would like to draw your attention to the fact that the REVEAL risk score includes all the various aspects that are important in the diagnosis and treatment of patients. Like which functional class they are. What are the comorbidities? Vital signs. Six minute walk tests. Also included in the REVEAL risk score, of course. Lab values, imaging values, function tests, and invasive hemodynamic parameters like the right heart catheterization, which we also had. The second thing that I would like to direct your attention to is the blue box on the right, which indicates that a one-point reduction in the risk score within 12 weeks is already associated with a 23% reduction in mortality at 12 months. I'd like to come back to this point on the next slide. What did we see? We saw that in the REVEAL risk score. Keeping in mind that this is a progressive, debilitating disease, patients show no spontaneous improvement. We saw that 43% had an improvement in the REVEAL risk score. That means at least a one-point increase for 43%, and stability for 29%. That means 29% were stable. So all in all, over 70% had either an improvement or stabilization of the REVEAL risk score. To put that into perspective. What I was saying on the last slide, a one point reduction in risk score within 12 weeks in our study was for 12 weeks. This is associated with a 23% reduction in relative risk of death at 12 months. So these are very promising signs that we are doing something good here. Taking the REVEAL risk score, which encompasses many aspects of the diagnosis and treatment of patients. If we consider another aspect, we've examined the risk score. How about the ability to move for the patients, which is functional class. On the right-hand side, you see the criteria for functional class. Class one is when there are no complaints at rest. Class four is where they are bedridden. Class two is characterized by mild complaints with movement and activity, and class three is marked by moderate or severe complaints during activity. So the goal is to improve the functional class. Practically, we had included classes two and three. So to improve it by at least one class, which would be lovely. What we observed was that 33%, which is seven out of 21 patients, showed an improvement in functional class. And we had, all in all, 86%. That means 18 out of 21 were either improved or stable in their functional class. Please keep in mind again that it is a progressive disease where there is actually no spontaneous improvement. So this is again a very promising sign. And functional class, of course, affects the daily activity of the patients. The more they can move, the better they feel. So this is, of course, also something very important which should be considered. Allow me then to delve into the hemodynamics. But before I do that in detail, I would just briefly like to tell you how we measured it. So what we did is we used CardioMEMS in close collaboration with Abbott. CardioMEMS is a device that permits daily noninvasive monitoring of pulmonary artery pressure. It measures it daily, and then one can retrieve the data wirelessly. The patients have the device, which operates while they are lying on a specific mat. Uh, one can record it and then, of course, build an area under the curve. Because usually what one does is have the patients lie on the mat for 20 seconds. That is taken as an average. And since our trial lasted for 12 weeks, we have approximately 85 measurements for each. So we have, all in all, over 1,500 measurements per patient, which is a substantial amount of objective data that we have collected from these patients. And what did we get there? Sten already mentioned that briefly. We have sustained reduction of mean pulmonary artery pressure and PAP area under the curve (AUC) in two thirds of the patients. That means 14 out of 21. You can see on the left-hand side of your screen the bars that are going down. That means there is a reduction in mean pulmonary artery pressure. What does that mean? That means, with the lowering of pulmonary artery pressure, the heart has somewhat less effort to work against. This is a good sign. You see in the middle a green graph bar. And that is actually the patient that we reported approximately one year ago, the remarkable patient case. That patient had already shown a very impressive reduction in impact. But you can see that there were many other patients who also had an even more pronounced reduction in mean pulmonary artery pressure. Allow me to briefly show you what that means on this slide. On the left-hand side, on the y-axis, you see the units, which represent the mean pulmonary artery pressure area under the curve. Days 1 to 85. What we have done is we have put these all together. And then you see the numbers -400, -200. What you have to do to compare to others is then divide this by 85. What does that mean? That means the special patient, the remarkable patient that we had, represented by the green bar, experienced a reduction of approximately two and a half to three millimeters of mercury, and it goes up to five millimeters of mercury. What does that mean? I'd like to put that into perspective and show you another independent trial which was looking at the pulmonary arterial diastolic pressure, which is similar, but not exactly the same. Here it was deemed that this is an independent predictor of mortality. If I may divert your attention to the left-hand side, where you see the black bars going downwards. If one reduces the mean pulmonary artery pressure by three, four, or five, you can see mortality goes down by 19, 24, or 30%. And we have that in our study where we have patients who have a reduction of mean pulmonary artery pressure of somewhere around two and a half to up to five. So again, very promising data, which we see because a reduction of impact is associated with a decreased mortality risk. So, all in all, allow me to summarize. The primary endpoint of safety and tolerability was met successfully. We have demonstrated a compelling positive impact on exploratory clinical parameters. And I would like to stress here that this is already over a 12-week treatment period. This is something to be remembered. Previously, we saw that the risk score was 43%. That is, nine out of 21 had an improvement in the risk score. And 71%, that is, 15 out of 21 either improved or had a stable risk score. And I showed you the importance of that. Functional class indicates the level of activity possible. 33%. That means seven out of 21 improved in functional class already over the 12 weeks. And all in all, 86% that is 18 out of 21 had either an improvement or stable functional class. When we examine the hemodynamics, where we have continuous monitoring providing very precise measurements, we observed that 67%, that is 14 out of 21, experienced sustained pressure reduction. So very much in line with what we had already reported earlier, one year ago. And this is, of course, again, very promising. In this small study, I would like to share with you a quote. And we're also going to hear from Dr. Who is one of the most active investigators in our trial, who was very pleased with it. And due to the results of what he saw in his patients, he's also someone who very much wanted his patients to continue in the trial. And the patients also voiced that they wanted to be in the compassionate use program. Actually, all of his patients have said that they want to continue the treatment with CS1. And maybe we can just briefly share what Dr. Sörensen has to say.

Unknown 1
37:19 - 37:37

I am very pleased with the positive outcomes we are seeing in our patients following treatment with CS1, their improvements in health and well-being are encouraging and reflect the potential effectiveness of the therapy. This progress reaffirms my commitment to advancing treatments that can make a meaningful difference in patients' lives with Pulmonary Arterial Hypertension.

Dr. Rahul Agrawal
37:39 - 38:24

Okay, so thank you very much for playing that. And this actually shows that he is only representative. And we have heard that from other investigators as well. The positive impact that they see. And they would like to continue their patients in the compassionate use program. So we are seeing very encouraging signs in the clinical trial in this Phase IIa trial. What I would like to do now is hand over to my dear colleague, Nick, who is head of our preclinical development, where we see some evidence that we would like to share with you. Nick, allow me to hand over to you. So thank you very much.

Nicholas Oakes
38:24 - 53:39

Much, Raoul. It's really a great pleasure to be part of this webcast and share some more insights that we've gained by combining our preclinical data with our clinical data, as well as diving more deeply into some of the clinical data that we have. So just to briefly outline what I will discuss in this section, I will refer to some very recent in-house evidence of reverse remodeling from preclinical data. I'll then talk about pulmonary vascular resistance, which is our indirect measure of reverse remodeling from the CS1 Phase IIa trial, and also then going to a group of remarkable responders that we have in this study, showing evidence consistent with reverse remodeling and also improved right ventricular function in the CS1 Phase IIa trial. And then also I will just finish off with some data that suggests that perhaps, we have already achieved the therapeutic exposures needed to obtain this reverse remodeling at rather low doses. So next slide. So first of all, I want to share with you some really beautiful preclinical data from a very closely related compound, CS014. Why do we think this is relevant? Well, because this compound has similar potency to CS1, and we know from a lot of preclinical data that not only is it effective on the primary target, which is HDAC inhibition, but it is also equally potent in several other measures of efficacy. So just to clarify, this slide speaks to a particular pathophysiological feature of PAH, which is really a hallmark of the pathophysiology of PAH. And that's shown in the histological pictures on the right hand side. And if we compare the healthy situation, which is the picture on the left, you can see that what's depicted here is a cross-section through a small artery of about 100 micrometers in diameter. And that's in the center of the field that you see. And surrounding that, the terminal air sacs that make up the lung tissue. And you can see that this artery is, is basically, very empty there. It has a thin wall, and there is no obstruction to the blood that would be flowing through it. In contrast, what you see to the right in this figure is a so-called plexiform lesion. Now here the endothelial cells have proliferated and occupied this central lumen of the artery. They make it very difficult for blood to flow through this vessel. And again, this is really a classic feature of clinical PAH. And if we now look at the data where the occurrence of these kinds of vessels has been quantified. In a well-used animal model. So this is the Sheehan hypoxia rat model, which has been used for basically every principle clinically used today. For PAH, what you can see in the leftmost histogram is that the occurrence in normal healthy animals is practically zero. And then, in the untreated placebo group, you can see that there is a high occurrence of these plexiform lesions. And then when we treat with this, the active ingredient of this one's analogue CS014, we see a very nice and robust dose-dependent reduction in the occurrence of these plexiform lesions. Next slide please. Oh, I should also say that in the histology we saw, we noted a marked reduction in fibrosis surrounding the vessels. Sorry about that. So, our next slide, please. So now, I want to take you back to the clinical trial results with CS1. We can't discuss plexiform lesions in the data we have today, but instead, we focus on a parameter that reflects the degree to which the vessels are obstructed in these patients. And that parameter is the pulmonary vascular resistance, as Dr. Rahul Agrawal mentioned previously. And basically, on the left-hand side of this diagram, you see the progressive obstruction of vessels with the pathogenesis of the disease. And then, underneath these cartoon diagrams of the small arteries being blocked, you see our hypothesis that CS1 will reverse this pathological change so that we will have more open vessels, precisely as I've shown you from preclinical data. So PVR is the hemodynamic parameter that best reflects reverse remodeling. Okay. To the data on the right-hand side, what you see in this figure is all the data for all the individual patients plotted here for PVR. And what's shown on the x-axis is the pre-treatment baseline value of PVR in Wood units, plotted against on the y-axis, the end treatment PVR in the patients. So that, if there was no alteration in PVR with treatment and no variation, all of these points would lie along this diagonal line, the red line. So if we take it as an example, there's a -50% shown here. This individual patient had a value in Modus units of 12 before being treated and six at the end of treatment. And actually, this is an absolutely remarkable change in PVR that we saw in this individual. There were several other patients who also showed very large changes. So in this slide, I've highlighted the patients who had significant changes. And these are shown, encompassed in this rectangle. And these individual patients showed reductions in PVR of between 35 and 51%, with a mean of 45%. Now, of those patients who responded in that manner, four out of five were actually in the low dose group. Now, how likely is it that we would see changes like this? Well, it turns out that it's extremely unlikely that we would see these changes by chance. In fact, we compared these reductions with standard of care treated placebo groups from a much larger trial, the Stellar study, which had hundreds of patients instead of our trial. And we're able to conclude statistically that the chances of this kind of reduction are extremely small. So next slide, please. Now, when we actually take those patients who responded and try to understand what else happened in these patients that stood out, and specifically, was there any evidence that right ventricular function was improved in those patients? So we could see that there was a very strong inverse relationship between the change in stroke volume in those patients and the reduction in PVR. And this group, we're calling the remarkable responder group. And so if we just take a look at this figure that is shown here. What we've plotted is the change in stroke volume on the y-axis versus the change in PVR on the x-axis. So those patients who responded remarkably are shown in this green field on the upper left-hand side of the figure. So what you can see is that as PVR was reduced in those individuals, the stroke volume markedly increased. And if we try to understand whether these changes in stroke volume were significant. Yes, they were because we know from the literature that changes of greater than ten milliliters in stroke volume are clinically significant, meaning that both patients have improved outcomes, and what we could see was that the changes were greater than ten milliliters in all of these patients. So we can conclude then that the reduction in PVR and the increase in stroke volume that we observed in these remarkable responders were clinically meaningful, and the magnitude of the increases in stroke volume was significant. And we have evidence that remodeling should result in decreased PVR. Uh, outside remodeling results in increased PVR. So this is the impact of the disease and worsened right function that's shown by this red constriction in the diagram below. And that CS1 reduces PVR and improves right heart function. Now, just bringing together all of the data that we have. So the preclinical data as well as the clinical data remind us that CS014 is an equipotent analog of the active ingredient of CS1. So what we've done in this slide, or in this diagram to the left, is to compare the exposures that were needed in order to see the reverse remodeling effects, including the reduction in the plexiform lesions, so that's represented by the green field at the bottom of that graph. The upper line in the green field represents the maximally efficacious exposure needed to achieve this reverse remodeling. And so what we could see was, if we compare these exposures for the preclinical studies against the exposures that were achieved in the clinical studies, we can see that we are far above the exposures needed at the high dose and slightly above them at the mid dose. So, the maximally effective preclinical unbound exposures correspond to the low to mid-dose levels in our Phase IIa clinical trial. And the majority of these remarkable PVR responders are actually in the low dose group. So next slide. So just to summarize what I've told you here, then: recently obtained preclinical data with CS014, again a very close analog equivalent to the active ingredient of CS1, demonstrates a dose-dependent reversal of remodeling of lung resistance arteries. In a preclinical model, a dose-dependent reduction of plexiform lesions, a reduction in fibrosis associated with pulmonary arteries, and maximal efficacy at equivalent exposures to CS1 Phase IIa trial. Lower dose range: 24% of the patients responded to CS1 with remarkably large reductions in PVR, consistent with the proposed reversal of pathological vascular remodeling. These reductions in PVR, between 35 and 51%, were strongly associated with robust increases in the right ventricular stroke volume of greater than ten milliliters.

Dr. Rahul Agrawal
53:39 - 53:40

Ventricular.

Nicholas Oakes
53:40 - 53:55

Stroke volume of greater than ten milliliters. So next slide. So with that I'd like to hand back to Sten to wrap up the meeting. Thank you very much.

Sten Sörensen
53:57 - 61:12

Thank you, Nick. Excellent presentation. Now, let's go to the conclusions. So we have positive topline results of the Phase IIa trial with the lead candidate, CS1, and PF next. And you have heard this data several times. I won't repeat it, but to summarize, we have successfully met the safety and tolerability, demonstrated improvement in REVEAL risk score, which is crucial for prognosis, functional class which is vital for quality of life, and impact, which is a prognostic factor for these patients. Very good data. The CS1 study, along with preclinical information, consistently supports the reversal of pathological remodeling. So we have a clear path forward, and we are engaging with regulatory authorities with the aim to pursue a pivotal trial for this drug in the future. So what is the path? Well, we're going to complete the analysis of the trial. We have announced the FLUIDDA collaboration and compassionate use. What's happening with that, and then the regulatory paths. Next slide please. So we will complete the analysis of the pH trial, possibly come back with more data to the market. And we'll, of course, take that data into our discussions with the FDA. Our regulatory path is aimed at pursuing a pivotal trial. But this data and our aim is to also achieve faster regulatory processes, if possible, for the drug. With regards to compassionate use. We have one patient dosed so far, and we have communicated that; we aim to have that data to show us clinical and other parameters. What will CS1 be able to achieve if we have achieved this in 12 weeks? What we will be able to achieve in longer studies, six months or a year, will be very exciting to follow. Florida partnership to document the impact of our drug on reverse remodeling, which Nick has so elegantly communicated with you today. We'd like to see the drug studied with cutting-edge technology on the pulmonary arteries in humans in a clinical setting, and we aim to do that with long-term use. And some of these patients will be the compassionate use patients. So that will be excellent to see next. So, this is the technology. And just to show you the press release to the left from this morning, showcasing our collaboration with FLUIDDA and how it appears. If you have a healthy pulmonary artery grid of vessels around and in the lungs, you can observe what happens to these vessels in PAH to the right. So this is what we'd like to see. Can we prevent progression or reverse into the left picture? Perhaps next. Concluding there, the communication around the top-line data and in-depth analysis. Let's look at Cereno and the path forward for the company. So, of course, we had, as I mentioned upfront, a portfolio of programs. And then let's look at some key upcoming milestones that are interesting. Next, please. Yes. So, I showed this upfront. So we have this portfolio RPA program which is getting more exciting by the day, I would say CS1 is one. And then we have our portfolio. And now we have some very interesting data beyond the reduction or prevention of thrombosis without bleeding. With CS014 we also have an impact, the dose-dependent impact on plexiform lesions in the pulmonary arteries. Thus, from our perspective, the portfolio is indeed hot. And, of course, thrombosis prevention. We have documented for our novel agent from the University of Michigan a prevention of thrombosis without increasing risk of bleed, as has been done also with CS014, as I mentioned. We hope and believe that this will be an attractive portfolio to discuss with potential partners. Discussions that are already ongoing. I would say without going into any details, our company and our portfolio have been exposed to several or many companies. I would say over this year in the start, and as we have moved into the fall expecting our top line data next. Key upcoming milestones include the compassionate use program, long-term data in the first part of next year, CS1, FDA pivotal study approval. We expect to get on the first part. We hope so by next year. Reverse remodeling impact of a drug in human pulmonary arteries, as measured with FLUIDDA's technology. And in the beginning of next year, or rather, in the spring. And then CS014 phase one completion is targeted for the end of Q2, and CS014 phase two approval by the end of next year, along with continued partnering, collaboration, or M&A activities. So by that, I'd like to conclude the presentation and I hope you found it interesting. You're all excited, and now I'll open up the webcast Q&A session. Before we proceed, I'd like to mention that we have quite a short session today, in respect to the time available. But you would also be welcome to send questions to this email here or either responsible Henry at questo@cerenoscientific.com. We'll do our best to answer those for you and publish them in some frequently asked questions on our website. In addition, as communicated here, we have a Capital Markets Day on October 17th at 1:30 p.m. In Stockholm, that will also be streamed, and we expect to have an extensive session on questions and answers with our people who are active either over Teams or on stage that day. So, now let's open this for questions from the audience and analysts first.

Operator
61:15 - 61:37

If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Joseph Hedden of ARC Securities. Please go ahead.

Unknown 2
61:40 - 62:17

Good afternoon. Thank you for taking my questions. And congratulations on this very encouraging data. So, I think you alluded at the end that it would be great to see what happens with longer treatment periods. So, I was just interested if you could share any details about how quickly the reductions in pressure were observed in responders during the trial, and did you notice deepening responses over the course of 12 weeks, indicating that perhaps with longer treatment periods, these patients could experience even greater improvements?

Sten Sörensen
62:18 - 63:08

It's a good question. I want to hand this over to Dr. Agarwal, our CMO, and I should also point out that the pressures you see, as measured with AUC, are actually the pressure load. So, the mean PAP (pulmonary arterial pressure) reduction that you see, multiplied by days measured, is the load on the right ventricle. And that's why the documentation here of two to five has a significant impact from 20 to 30% reduction in mortality over a period, as Dr. Agrawal mentioned. But Rahul, please, take the question forward.

Dr. Rahul Agrawal
63:09 - 63:55

Sure. Thank you very much. And this is, of course, a very important aspect. We are also looking into that aspect, keeping in mind the points you alluded to. We have only used 12 weeks so far. So we are capturing promising signals, particularly with the immense technology that has allowed us to collect a significant amount of data. As I was saying, over 85 to 90 days, we have captured nearly 1,500 datasets for these patients. And yes, we see very promising results. And if one keeps in mind this is a progressive, continuous disease. We hope to see, of course, better and even more pronounced results over a longer treatment period. Absolutely.

Unknown 2
63:59 - 64:27

I think it's great. And perhaps if I could just follow up on the patients where you saw the most impressive effect on PVR, and the ones you are calling the super responders? But did they correspond exactly to those who have the biggest improvements or who improve on REVEAL risk scores and functional class? Is everything perfectly aligned in that respect?

Sten Sörensen
64:28 - 64:34

Again, I'll leave that up to you, Rahul, to comment on.

Dr. Rahul Agrawal
64:34 - 65:11

Yes, in an ideal scenario, we would say that everything is aligned. All the parameters are. But of course, patients react differently. As I said, this is a very small trial. It's a Phase IIa trial. Several patients did show reductions in PVR or improvements in hemodynamics in the right direction. But we're talking here, as Nick had very nicely demonstrated, about five or six patients currently. And we hope that in a larger group we can observe a more sustained effect. And we can demonstrate that in a more reliable fashion.

Sten Sörensen
65:15 - 65:24

Okay. So, I hope that was helpful. Uh, Joseph, do we have other questions from the analyst audience?

Operator
65:28 - 65:34

The next question comes from Aaron Arteaga from Edison Group. Please go ahead.

Unknown 3
65:36 - 65:56

Hi there. Thanks very much for the presentation and for taking my question. Um, so your press release has sort of mentioned engaging with authorities through a pivotal trial. And I just wanted to get your thoughts on whether you think one randomized trial will be sufficient for regulators, given that cities have had two late-stage trials.

Sten Sörensen
65:56 - 66:22

Thanks. It's a very good question. Thanks for being present and asking that question. And, you know, I'm sure, here again, Rahul will answer. I can mention that the approach with this kind of data, the aim is likely to be three trials. So, but again I’ll leave that to Rahul to comment on.

Dr. Rahul Agrawal
66:23 - 67:22

Thank you very much then. And yes, this is a very important question. Please keep in mind that we're talking about a rare orphan indication. We already have orphan drug designation. The authorities are very open to discussions, especially if the data indicates that it's a safe and well-tolerated drug. As you know, there is experience with the key component of CS1 for many years. And we have shown good results. So we think we have very good data to go there and engage the regulatory bodies. And I have previous experience from my times at larger pharmaceutical companies, also in PH, where one can approach them and they are very open to an adaptive trial design. Phase IIb trial, as Sten was mentioning. And we think we have some very good arguments here. So we'll pursue this? Absolutely.

Sten Sörensen
67:26 - 67:28

Any more questions here?

Unknown 3
67:28 - 67:56

And one more, if I may. So, in terms of the next phases of development, we see that you're open to various M&A options and licensing partners. Appreciated. It's pretty early stage, but with the sort of two-stack inhibitors that you've got in your portfolio, how do you see discussions playing out with potentially interested parties? Is there a chance this could be for both assets? Or do you think that you'll see these as individual programs going forward? Thank you.

Sten Sörensen
67:57 - 70:05

A very good question. And, you know, there is, of course, a strategy behind Cereno, pursuing these two assets that is, I would say, 5 or 6 years old. So we have our business and development strategy. Thus, we have achieved what we set out to pursue many years ago. So, what you are seeing here, playing out in data from the Phase IIa trial with CS1, is data related to thrombosis with CS014 before and now plexiform lesions. It's all part of a plan that we keep close to our chest, but we believe that this will be an attractive portfolio for the majors pursuing cardiovascular disease, with the ambition to be able to address the root cause of the disease progression in several indications. So that's our plan and exactly how those discussions will play out. And we will have to see. And so, we haven't really disclosed the end, or, you know, we're not discussing the end of these programs and the full scope of what can be pursued. We have previously communicated to the market and to potential partners the many indications that can be targeted if you have an impact on inflammation, endothelial dysfunction, fibrosis, and vascular remodeling in the vessels and the heart. There are many patients with cardiovascular diseases that have this complex pathophysiology to various degrees. So agents that can do what we have seen so far with HDAC inhibition would be and will be very attractive, I think.

Unknown 3
70:08 - 70:12

Thanks very much. No more questions. And congrats again on the positive data.

Sten Sörensen
70:12 - 70:16

Thank you. Additional questions.

Operator
70:16 - 70:23

Perhaps there are no more questions at this time. So, I hand the conference back to the speakers for any written questions.

Sten Sörensen
70:25 - 71:08

Okay, thank you. I don't know if I'm on. I have stored some questions that I received on my phone. Bear with me. Uh, I think many of these questions have been responded to. I'll see here. So, could you please comment on the conclusion of the optimal dose being found in the lower dose? And, um, what's the hypothesis of this? I think Nicholas Oakes referred to this to some extent here. Um, so I think that question has already been answered. Why did you pull the doses is another question here. And perhaps Rahul, you could take that question.

Dr. Rahul Agrawal
71:09 - 71:32

Sure, very gladly; I had mentioned that briefly also in my presentation. We have pulled it because we had seen the PK PD data which were pointing in that direction. That means pharmacokinetic and pharmacodynamic data which were pointing in that direction. And number two, because of the small sizes in each group, we thought it best to pool the data. So those were definitely good reasons to do so.

Sten Sörensen
71:34 - 75:08

Good. Thank you, Rahul. Do you expect to see further improvement over a longer treatment period? I believe that question has just been addressed. Will you be sharing more information on the exploratory efficacy parameters as we progress? You move on with your analysis. Yes, that is likely to happen. And we are planning, hopefully planning here a publication in a reputable journal or several, about that data. And we'll get more data coming out of the trial when we finalize the analysis into the final report. Um, what are your next steps? When do you foresee that the pivotal trial can be initiated? Um, well, we hope that we'll be able to get regulatory approval for our programs moving forward. And we are aiming for a pivotal trial. We hope we'll get that approval by the first half of next year. And then preparations are going on from now and moving towards the start of such a trial, which we haven't really disclosed yet when that would be. I would offer here that it might be, you know, in early 2026. Um, so, possible sub-questions. What will the collaboration with Abbott look like after the trial? We've had a very good collaboration with Abbott in this trial. And we think one part of the very interesting data we have here is the sustained clinical reduction of mean pulmonary arterial pressure over time, with these 1,500 to 2,000 measurement points for each patient. Now, the question is, of course, how will that CardioMEMS technology be useful as we move forward in the programs? And I'll wait with that. Until we have defined how that technology could be useful in our programs for getting this drug eventually to the patients through a pivotal trial. I think those are the main questions here. I don’t know if we have any other questions to address. I think we perhaps should close the Q&A session for now. And then just thank everyone for being part of this Webcast, and especially the shareholders for supporting our journey to provide, develop and provide valuable therapeutics to patients that are in dire need of those, and especially addressing root causes of diseases with safe and effective therapies. Please send your questions to this email and request of Cereno Scientific. Please send your questions to this email at Cereno Scientific.com, and we'll try to answer them. And of course, we'd love for you to show up at our Capital Markets Day either digitally because it will be streamed, or in person at Post-Gazette in Stockholm at 1:30 p.m., October the 17th. And by that, I'd like to conclude this webcast, and I hope you share the excitement of this data and Cereno's future with our programs. Thank you.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…